A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Status:
Not yet recruiting
Trial end date:
2023-02-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab
combination treatment in participants with active psoriatic arthritis (PsA) and inadequate
response (IR) to a prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by
assessing clinical response compared with guselkumab monotherapy.